National Storage Mechanism | Additional information
RNS Number : 4852Q
Societe Generale SA
26 February 2021
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGSBY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

Société Générale S.A.

Company dealt in

               Willis Towers Watson plc

Class of relevant security to which the dealings being disclosedrelate (Note 2)

US$0.000304635 ordinary shares

Date of dealing

25/02/2021

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

808,375

0.63

1,603

0.00

(2) Derivatives (other than options)

1,428

0.00

8,131

0.01

(3) Options and agreements to purchase/sell

0

0.00

0

0.00

Total

*1,621,984

*1.26

9,734

0.01

                               

* Include the holding of shares 812,181 on borrow products

 

               

(b)        Interests and short positions in relevant securities of thecompany, other than the class dealt in (Note 3)

 

Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

 

 

(3) Options and agreements to purchase/sell

 

 

 

 

Total

 

 

 

 

 

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit USD (Note 5)

Purchase

96

224.27

Purchase

1,708

224.27

Purchase

100

225.46

Purchase

16

226.45

Purchase

12

225.73

Purchase

100

226.55

Purchase

35

226.61

Purchase

100

224.43

Purchase

9

226.66

Purchase

36

226.5

Purchase

21

226.56

Purchase

9

226.56

Purchase

9

226.61

Purchase

36

226.61

Purchase

100

226.61

Purchase

15

226.98

Purchase

9

225.4

Purchase

97

225.38

Purchase

3

226.74

Purchase

10

226.91

Purchase

98

226.87

Purchase

99

226.72

Purchase

17

226.85

Purchase

1

226.72

Purchase

7

226.73

Purchase

2

226.87

Purchase

8

226.92

Purchase

100

224.22

Purchase

9

227.21

Purchase

40

225.18

Purchase

8

225.18

Purchase

52

225.18

Purchase

100

226.57

Purchase

50

223.7

Purchase

50

223.7

Purchase

100

227.37

Purchase

3,040

224.27

Sale

5

226.61

Sale

7

226.61

Sale

25

226.46

Sale

1

226.588

Sale

1

226.588

Sale

9

226.588

Sale

5

226.608

Sale

2

226.588

Sale

2

226.588

Sale

22

226.608

Sale

2

225.21

Sale

100

225.23

Sale

23

225.21

Sale

61

225.21

Sale

14

225.21

Sale

100

224.29

Sale

100

224.25

Sale

57

226.46

Sale

16

224.35

Sale

22

224.14

Sale

78

224.14

Sale

1,444

224.27

Total Purchases

6,302

 

Total Sales

2,096

 

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit USD

(Note 5)

 

 

 

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

2.       OTHERINFORMATION

 

Agreements, arrangementsor understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 
relevant securities to which any derivative referred to on this form is referenced. If none, this
should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            No

 

Date of disclosure

26/02/2021

Contact name

Société Générale - Disclosure team

Telephone number

+33 1 42 14 92 74

If a connectedEFM, name of offeree/offeror with which connected

 

If a connectedEFM, state nature of connection (Note 10)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEFIFVDFIIRFIL